[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vascular-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vascular-dementia":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,50,77,93,116,147,180,216,240,267,288,312,340,363,393],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100634883","retinal-hyperspectral-imaging-in-neurodegenerative-diseases-100634883",false,"NCT07545473","Retinal Hyperspectral Imaging in Neurodegenerative Diseases","Inclusion Criteria:\n\n1. Aged over 30 years.\n2. Have dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2 or vascular dementia (age-matched and sex-matched controls will also be recruited).\n3. With the exception of participants with Parkinson's disease and Lewy body disease, for whom clinical examination by a neurologist is sufficient to establish a clinical diagnosis of probable dementia with Lewy Body or probable Parkinson disease dementia, all participants must have previously undergone at least of one of the following tests to help to confirm a clinical diagnosis of dementia or neurodegenerative disease: genetic tests, blood biomarker tests (amyloid, tau, neurofilament light), a brain amyloid beta PET scan, or cerebrospinal fluid tests.\n4. Have a minimum best corrected visual acuity level of 6\u002F60 in both eyes and no major eye problems, such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy.\n5. Be willing to participate in the study and attend the Centre for Eye Research Australia.\n6. Be accompanied by a friend or family member.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n3. Known contraindication to pharmacological pupil dilation\n4. Any condition that, in the investigator's opinion, would compromise participant safety or image quality",true,"ALL","30 Years",{"count":19,"type":20},930,"ESTIMATED","INTERVENTIONAL",[23],"NA","Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting \"hypercube\" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.",[26,27,28,29,30,31,32,33],"Dementia","Neurodegenerative Diseases","Alzheimer Disease","Parkinson Disease","Frontotemporal Dementia","Vascular Dementia","Lewy Body Disease","Niemann-Pick Diseases",[35,36],"Hyperspectral imaging","Retina","RECRUITING","2026-04-21",{"date":40,"type":41},"2026-04-22","ACTUAL",{"date":43,"type":41},"2021-10-11",{"date":45,"type":20},"2028-12-31",{"name":47,"class":48},"Center for Eye Research Australia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":49},"100525332","the-swedish-biofinder---primary-care-study-100525332","NCT06120361","The Swedish BioFINDER - Primary Care Study","ADetect","Inclusion Criteria:\n\n1. The patient seeks medical help because of cognitive symptoms experienced by the patient and\u002For informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.\n2. The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.\n3. Age ≥40 years\n4. Subjective cognitive decline, mild cognitive impairment or mild dementia\n\nExclusion Criteria:\n\n1. Already diagnosed dementia\n2. Significant unstable systemic illness or organ failure that makes it difficult to participate.\n3. Current significant alcohol or substance misuse.\n4. Refusing investigation at the Memory clinic\n5. Cognitive impairment with acute onset due to stroke\n6. The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.","40 Years",{"count":59,"type":20},1200,"OBSERVATIONAL","The overall aim of the study is to improve the diagnostic accuracy of AD and cognitive impairment in primary care settings to ensure better care and treatment as well as facilitate correct referrals to specialized memory clinics. The investigators will strive to recruit diverse and representative populations of patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and mild dementia. The specific aims of the study are to:\n\n1. Improve the detection of mild cognitive impairment (MCI) and dementia in primary care.\n2. Develop and evaluate cognitive tests, blood-based biomarkers and brain imaging methods that are suitable for accurate and early diagnosis of Alzheimer's disease (AD) in primary care.\n3. To prospectively validate plasma AD biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in primary care.\n4. Determine whether blood AD biomarkers improve patient management in primary care.",[63,64,65,28,32,66,31],"Mild Dementia","Mild Cognitive Impairment","SCD","Frontotemporal Degeneration",[68],"Primary care, early diagnosis, blood, biomarkers, cognitive testing","2026-04-01",{"date":71,"type":41},"2026-04-06",{"date":73,"type":41},"2020-01-01",{"date":45,"type":20},{"name":76,"class":48},"Skane University Hospital",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":49},"100525490","the-swedish-biofinder---memory-clinic-study-100525490","NCT06122415","The Swedish BioFINDER - Memory Clinic Study","Validate","Inclusion Criteria:\n\n1. Under investigation for cognitive symptoms at the Memory clinic.\n2. Cerebrospinal fluid and blood sampling is planned to be done as part of clinical practice even if the patient is not taking part of this study.\n\nExclusion Criteria:\n\n1. Not undergoing CSF or blood sampling as part of clinical practice.\n2. Not undergoing cognitive testing as part of clinical practice.",{"count":59,"type":20},"The diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blood biomarkers with high diagnostic accuracy, and the investigators now want to investigate whether they can eventually replace cerebrospinal fluid tests. This is because blood tests are much more cost-effective and significantly easier for patients compared to cerebrospinal fluid tests.\n\nIn this study, 1200 patients undergoing clinical evaluations at the Memory Clinic, Skåne University Hospital in Malmö, are included for blood and cerebrospinal fluid sample collection. The blood samples are sent for analysis using the new blood biomarkers. Subsequently, the results are compared with those from the clinical analysis of cerebrospinal fluid to determine how well they perform in routine clinical practice as an alternative to cerebrospinal fluid tests and whether the blood test improves patient care. This comparison is carried out by the attending physician in three steps:\n\n1. Assessment without access to the results of either the blood test or cerebrospinal fluid test.\n2. Assessment with access to only the results of the blood test.\n3. Assessment with access to the results of both the blood test and cerebrospinal fluid test.\n\nAim 1) To prospectively validate plasma Alzheimer's disease (AD) biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in a specialist memory clinic.\n\nAim 2) Determine whether blood AD biomarkers improve patient management in specialist memory clinic settings.",[63,64,65,28,32,66,31],{"date":71,"type":41},{"date":89,"type":41},"2022-12-01",{"date":91,"type":20},"2026-12-31",{"name":76,"class":48},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":49},"100548083","retinal-vessel-leakage-in-cerebral-small-vessel-disease-100548083","NCT06416371","Retinal Vessel Leakage in Cerebral Small Vessel Disease","Retinal Vessel Leakage in Cerebral Small Vessel Disease: a Sub-study of the Mild Stroke Study 3","Inclusion Criteria:\n\n* Membership in the Mild Stroke Study 3 cohort\n* Contrast enhanced MRI within 12 months\n* Clear optical media in both eyes, as assessed by study investigator\n* Best corrected visual acuity (near vision) ≥N36\n\nExclusion Criteria:\n\n* Any condition known to cause retinal leakage (i.e., worse than background diabetic retinopathy, retinal vein occlusion, active uveitis, wet age-related macular degeneration, malignant hypertension)\n* Previous treatment for retinal leakage (retinal laser, intravitreal anti-VEGF)\n* Recent eye surgery\n* Shallow anterior chambers as assessed by torch test\n* Pregnancy, renal failure\n* Severe dementia\n* Known allergy to fluorescein\n* History of allergy such as food or drug induced urticaria or history of bronchial asthma\n* Any other severe or acute medical or psychiatric conditions\n* Inability to give informed consent","18 Years",{"count":102,"type":20},40,"The goal of this observational study is to learn about leakage from retinal vessels in cerebral small vessel disease. The main questions it aims to answer are:\n\n* Does retinal vessel leakage occur in cerebral small vessel disease?\n* If it does, is the severity of retinal vessel leakage similar to the severity of cerebral small vessel disease generally?\n\nParticipants will be tested using fluorescein angiography. This involves an intravenous injection of fluorescent dye, and is a very sensitive way to find leakage from retinal blood vessels.\n\nParticipants will have already had brain scans and other examinations and tests to measure the severity of their cerebral small vessel disease. Our new retinal images will complement the information from these previous tests.",[105,106,31],"Cerebral Small Vessel Diseases","Lacunar Stroke","2026-03-02",{"date":109,"type":41},"2026-03-04",{"date":111,"type":41},"2025-01-13",{"date":113,"type":20},"2029-02-15",{"name":115,"class":48},"University of Edinburgh",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":15,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100585493","a-study-that-collects-participant-data-and-biospecimens-to-analyze-pathogenic-exosomes-that-mediate-increased-vascular-dementia-risk-in-individuals-with-herpes-zoster-100585493","NCT06903078","A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster.","Pathogenic Exosomes During Herpes Zoster Mediate Increased Vascular Dementia Risk.","R01","Inclusion Criteria:\n\nAt the Screening Visit (Visit 1\u002FDay 1), all participants must meet all the following criteria in order to be considered for participation in the study:\n\n1. Be a male or female ≥ 18 years of age.\n2. Present to clinic for routine dermatologic evaluation with or without rash.\n3. Are willing and able to complete study visits and procedures, and able to effectively communicate with the investigator and other study personnel.\n4. Have adequate venous access and are willing to undergo venipuncture for blood draws.\n5. Able to provide written informed consent prior to any study procedures. Additional inclusion criteria for Herpes zoster (HZ) participants,\n6. Present with acute, vesicle-stage HZ that has not been treated with antiviral therapies\n7. Are willing and have reliable transportation to complete additional follow-up visits at 7 days, 1 month, 3 months, 6 months, and 12 months after initial visit for acute HZ.\n\nExclusion Criteria:\n\nAt the Screening Visit (Visit 1\u002FDay 1), participants meeting any of the following criteria will be excluded from participation in the study:\n\n1. Female individuals who are pregnant or breast-feeding.\n2. Receiving systemic or topical antivirals for varicella zoster virus (VZV).\n3. Sensitivity or allergy to systemic or topical antiviral medications for HZ.\n4. History of diagnosed HZ within the last 8 years.\n5. Received a HZ vaccine (e.g., Zostavax®\u002FShingrix®) within the last 8 years.\n6. Received any vaccinations within the last 3 months.\n7. Currently taking immunosuppressive therapies, including medications and radiation.\n8. Currently taking any anticoagulants.\n9. History of any coagulation disorder(s).\n10. History of end-stage renal disease or uremia.\n11. History of end-stage liver disease.\n12. History of HIV.\n13. Have had a COVID-19 infection in last 3 months.\n14. Any history of non-skin cancers within the last 3 months.\n15. History of serious infection requiring hospitalization in the last 3 months.\n16. Prior history of cardiovascular accident or myocardial infarction within the last 12 months.\n17. Prior cerebrovascular accident in the past 12 months.",{"count":125,"type":20},375,"The purpose of this observational research study is to study if patients with herpes zoster, also known as Shingles, have a higher risk of vascular dysfunction (problems with blood vessels, including stroke) and vascular dementia (problems with mental decline as a result of decreased blood flow to the brain) compared to patients without herpes zoster.\n\nPatients are evaluated based on the group they are assigned too:\n\n1. Herpes Zoster (HZ) Group: individuals presenting with untreated herpes zoster. These participants will have 6 visits:\n\n   * Day 1 = 1st day presenting to clinic with acute zoster\n   * 7 days post zoster\n   * 1 month after Day 1\n   * 3 months after Day 1\n   * 6 months after Day 1\n   * 12 months after Day 1\n2. Control Group: individuals without herpes zoster o Day 1 (only 1 visit will be completed)\n\nThis study does not have a study medication\u002Fdevice. Standard of care for all patients will be followed.",[128,31],"Herpes Zoster (HZ)",[130,131,132,133,134,135,136],"RO1","1R01AG085406-01","Herpes Zoster","Shingles","Dr. Stephen Tyring","Dementia risk HZ","VZV","2025-12-04",{"date":139,"type":41},"2025-12-11",{"date":141,"type":41},"2025-02-13",{"date":143,"type":20},"2030-08",{"name":145,"class":48},"Center for Clinical Studies, Texas",2,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":158,"conditions":159,"keywords":165,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":49},"100612893","predictors-of-emergency-department-use-in-frail-patients-100612893","NCT07259499","Predictors of Emergency Department Use in Frail Patients","Towards an Integrated Care System for the Assistance of Patients With Chronic Diseases, Multimorbidity, Frailty, and Polypharmacy","THE-Spoke 10","Inclusion Criteria:\n\n* fluency in Italian language,\n* age higher than 64 years,\n* loss of autonomies of daily living as assessed by the Katz Activities of Daily Living or in the Lawton Instrumental Activities of Daily Living questionnaires,\n* having performed routinary blood exams in the 6 months prior to recruitment\n* having performed head neuroimaging feasable for cerebrovascular burden assessment, i.e., Magnetic Resonance Imaging (MRI) or computed tomography (CT), in the 6 months prior to recruitment.\n\nExclusion Criteria:\n\n* withdrawal of the informed consent","65 Years",{"count":157,"type":20},110,"When admitted to the emergency department (ED), elderly non-autonomous patients show high risk of adverse health outcomes. The prompt identification of ED use risk factors in such population is hence needed. While cognitive impairment is a known clinical risk factor, biomarkers of most prevalent dementias have been scarcely investigated as possible ED use predictors. Within this context, this prospective study aims at exploring whether plasma phospho-tau181 and cerebrovascular burden can predict ED use at 6 months in elderly non-autonomous patients, irrespective of frailty.",[160,31,161,162,163,164],"Alzheimer s Disease","Frailty","Elderly","Emergency Department Visits","Autonomy",[166,167,168,161,169,162,170],"phosphorylated tau 181","dementia","Emergency Department","Autonomies","cerebrovascular","2025-11-20",{"date":173,"type":41},"2025-12-02",{"date":175,"type":41},"2023-11-19",{"date":177,"type":20},"2025-12-31",{"name":179,"class":48},"University of Pisa",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":187,"enrollmentInfo":188,"targetDuration":190,"studyType":60,"phases":4,"briefSummary":191,"conditions":192,"keywords":197,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100556794","improving-prognostic-confidence-in-neurodegenerative-diseases-causing-dementia-using-peripheral-biomarkers-and-integrative-modeling-100556794","NCT06529744","Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling","CRND TorCA","Inclusion Criteria:\n\n* Possible or probable diagnosis of MCI or early dementia\n* Age 30-95\n* Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits.\n* Must, in the opinion of the site investigator, be able to complete most study procedures.\n\nExclusion Criteria:\n\n* Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study. Exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.","95 Years",{"count":189,"type":20},500,"1 Year","To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).",[26,28,193,31,30,64,194,195,29,196],"Dementia With Lewy Bodies","Corticobasal Syndrome","Progressive Supranuclear Palsy","Primary Progressive Aphasia",[198,167,199,200,201,202,203,204,205,206],"alzheimer's disease","dementia with lewy bodies","vascular dementia","frontotemporal dementia","mild cognitive impairment","corticobasal syndrome","progressive supranuclear palsy","parkinson's disease","primary progressive aphasia","2025-11-17",{"date":171,"type":41},{"date":210,"type":41},"2023-11-11",{"date":212,"type":20},"2027-11",{"name":214,"class":48},"University Health Network, Toronto",4,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":223,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":49},"100604401","evaluation-of-cerogrin-for-auricular-vagus-nerve-stimulation-in-vascular-dementia-or-vascular-mild-cognitive-impairment-100604401","NCT07149038","Evaluation of Cerogrin for Auricular Vagus Nerve Stimulation in Vascular Dementia or Vascular Mild Cognitive Impairment","A Single-Center, Randomized, Double-Blind Feasibility Trial Assessing the Initial Efficacy and Safety of Cerogrin, a Medical Device for Auricular Vagus Nerve Stimulation, in Improving Cognition in Patients With Vascular Dementia or Vascular Mild Cognitive Impairment: A Comparison With Sham Control","Inclusion Criteria\n\n* Adults aged 55 to 89 years.\n* Diagnosed with vascular dementia or vascular mild cognitive impairment within 1 year before screening, with subcortical lesions confirmed on MRI.\n* For both diagnoses:\n* Severe white matter hyperintensity on MRI (Fazekas scale: deep white matter ≥ 2.5 cm or caps\u002Fbands ≥ 1.0 cm).\n* Z-score \\\u003C -1.0 SD in at least one cognitive domain (adjusted for education, age, and sex).\n* For vascular dementia: independence in daily living impaired.\n* For vascular mild cognitive impairment: independence in daily living preserved.\n* K-MMSE-II score ≥ 18 and CDR score 0.5 to 1.0 at screening.\n* Stable cognitive-enhancing medication (if applicable) for ≥4 weeks before baseline.\n* Availability of a caregiver (at least 8 hours\u002Fweek contact).\n* Females of childbearing potential: agreement to use medically acceptable contraception during the study.\n* Provided written informed consent.\n* Willingness to comply with study protocol.\n\nExclusion Criteria\n\n* Dementia other than vascular dementia (e.g., Alzheimer's disease, Lewy body dementia, frontotemporal dementia).\n* Conditions causing cognitive decline (e.g., uncontrolled metabolic diseases, CNS infections, cerebrovascular disease, traumatic brain injury, Parkinson's disease).\n* Severe psychiatric disorders (e.g., major depression, schizophrenia, substance abuse).\n* Serious unstable physical conditions.\n* MRI contraindications (e.g., claustrophobia, metal implants, contrast agent allergy).\n* Auricular skin disease or condition preventing device use.\n* Inability to comply with study procedures.\n* Pregnancy or breastfeeding.\n* Participation in other clinical trials within 30 days before screening.\n* Any other condition deemed inappropriate for participation by the investigator.","55 Years","89 Years",{"count":226,"type":20},24,[23],"This clinical trial evaluates the preliminary effectiveness and safety of Cerogrin, a medical device developed by Neurogrin Inc. for auricular vagus nerve stimulation, in patients with vascular dementia or vascular mild cognitive impairment. Given the limited availability of effective pharmacological treatments for these conditions, the study aims to assess whether Cerogrin can enhance cognitive function through non-invasive neuromodulation.\n\nTwenty-four participants will be randomized to receive either the active Cerogrin device or a sham (non-stimulating) device. Daily use will occur at home for 30 minutes over a four-week intervention period. The full study duration, including baseline assessments and follow-up, will span up to three months. During this period, cognitive function, neural activity, and safety outcomes will be systematically evaluated. This feasibility trial represents a critical step toward expanding therapeutic options for vascular cognitive impairment.",[31,64],"2025-11-14",{"date":232,"type":41},"2025-11-18",{"date":234,"type":41},"2025-10-15",{"date":236,"type":20},"2026-12-30",{"name":238,"class":239},"Neurogrin Inc.","INDUSTRY",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":49},"100518743","cognitive-and-vascular-functioning-following-tbi-100518743","NCT06034509","Cognitive and Vascular Functioning Following TBI","Inclusion Criteria:\n\n1. Active duty uniformed SM or Veteran who is currently eligible for treatment at WRNMMC (i.e., Defense Enrollment Eligibility Reporting System (DEERS)-eligible).\n2. Ability to read, write, and speak English.\n3. Ability to provide informed consent.\n4. NICoE Intensive Outpatient Program (IOP) or NatHx Study comprehensive evaluation ≥3 years prior to current evaluation with valid neuropsychological test results.\n5. Consent to allow access to prior research data collected through the NICoE TBI Neuroimaging Core Project or NatHx Study and consent to allow access to at least 1 prior blood specimen previously collected through these studies or the DoD Serum Biorepository.\n\nAdditional TBI Inclusion Criteria\n\n1\\. History of at least one mild, moderate, severe, or penetrating TBI \\> 3 years prior to enrollment. TBI will be diagnosed if any one of the following criteria immediately after the injury is met and attributed to the brain injury, rather than environmental\u002Fpsychological\u002Fother injury factors (DoD-VA criteria246):\n\n1. Loss of consciousness (LOC) or post-traumatic amnesia (PTA)\n2. Alteration of consciousness (AOC)\n3. Evidence of neurologic dysfunction\n4. TBI-related abnormality on structural neuroimaging (either CT or MRI). Additional Healthy Control Criteria\n\n   1. History of military deployment.\n   2. Low history of blast exposure (i.e., \\\u003C10 blasts) Additional Blast Control Criteria\n\n   \u003C!-- -->\n\n   1. History of significant blast exposure (i.e., exposure to ≥ 10 blasts)\n\nExclusion Criteria:\n\n1. Disabling neurologic or psychological disorders such as autism, cerebral palsy, developmental disorder, stroke, brain tumor, multiple sclerosis, meningitis, encephalitis, brain abscess, vascular malformation, pre-injury epilepsy, schizophrenia, bipolar disorder, personality disorder\n2. Diabetes mellitus requiring drug treatment\n3. Hypertension requiring more than 1 antihypertensive drug to control BP\n4. History of myocardial infarction or other systemic vasculopathies\n5. Dementia diagnosis at initial NICoE\u002FNatHx Study assessment","74 Years",{"count":248,"type":20},300,"This observational study will examine the association of chronic traumatic cerebrovascular injury and cardiovascular risk factors with TBI-related cognitive impairment and vascular dementia. Cerebrovascular, inflammatory, and neurodegenerative blood biomarkers as well as clinical and neuroimaging data",[251,252,31],"Traumatic Brain Injury","Cognitive Decline",[251,252,31,254,255,256],"Blood Biomarkers","Cerebrovascular Reactivity","Military","2025-09-22",{"date":259,"type":41},"2025-09-26",{"date":261,"type":41},"2023-11-27",{"date":263,"type":20},"2027-05",{"name":265,"class":266},"Walter Reed National Military Medical Center","FED",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":49},"100539025","the-brain-app-phase-2-sbir-100539025","NCT06298474","The BRAIN App (Phase 2 SBIR)","The BRAIN App (Phase 2 SBIR): Building Relationships Using Artificial Intelligence and Nostalgia","Inclusion Criteria:\n\n* 65+ years old\n* Clinical diagnosis of dementia (any type)\n* Able to speak conversational English\n\nExclusion Criteria:\n\n* Completely unable to communicate verbally\n* Serious visual or hearing impairments\n* Signs of rapid decline over the last three months (based upon staff report)",{"count":275,"type":20},120,[23],"There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Association, 2018). Responsive behaviors and dysfunction of the dementia care triad-i.e., the PLWD, professional Care Partner (CP), and Family Member (FM)-are inexorably linked. The emergence of responsive behaviors can lead to disruption of the triad's function. Thus, it is imperative to maintain positive relationships and a high quality of life (QoL) within the triad to reduce BPSD. Cognitive Stimulation Therapy (CST) has demonstrated improvements in QoL and relationships for PLWD. CST is a psychosocial intervention that promotes communication and engagement in PLWD via a structured program of meaningful and enjoyable theme. While clinical trials have shown improvement in cognition and QoL, the potential large-scale impact of CST has been hampered by low adherence, with less than 40% completing trials. One likely reason for the low adherence to CST is the reliance on generic and non-digital tools (e.g., paper-based agendas, tools, DVDs, and board games) in facilitating the intervention. That is, even though CST aims to be personalized, the specific interventions used in the field tend to be generic and not tailored to each PLWD's specific interests. The use of digital technology to implement CST would offer considerable advantages to expand and personalize the range of stimulation content and provide a means for monitoring responses, optimizing protocols, and promoting adherence.\n\nThe proposed Phase II study will involve the continued development and evaluation of a multi-faceted software platform called \"Building Relationships using Artificial Intelligence and Nostalgia\" or BRAIN. The BRAIN Platform will be the first-ever Artificial Intelligence (AI) powered CST digital therapy platform for PLWD. The platform, which has been shown to be effective in an initial Phase I clinical trial, has three main goals: to improve the quality of life of PLWD, to reduce BPSD in PLWD, and to foster positive relationships between members of the care triad. The proposed Phase II project has the following Specific Aims: 1. Create an improved Beta version of the BRAIN Platform's eight components: (1) the Admin Management Dashboard, (2) the Annotation Dashboard, (3) the Log Viewer, (4) the Content Management System (CMS), (5) the Private CMS, (6) the Control App, (7) the Home App, and (8) the Training Dashboard. 2. Fine-tune the different classes of AI algorithms-i.e., behavioral analytics, personalized content recommendation, and personalized program generation-in the BRAIN app such that they can (a) recognize and track 12 distinct behaviors and indicators of PLWD, (b) use these behavioral traits as a basis for automatically rating the relative success of each activity, and (c) automatically recommend personalized activities that are likely to be successful for individual PLWD. 3. Conduct a Cluster Randomized Trial (CRT) of the BRAIN App to examine the app's impact on engagement\u002Faffect, quality of life, and responsive behaviors. 4. Examine satisfaction and ease of use of the app for PLWD, LTC staff, and FMs.",[26,28,31],"2025-06-16",{"date":281,"type":41},"2025-06-19",{"date":283,"type":41},"2025-05-15",{"date":285,"type":20},"2026-07-30",{"name":287,"class":239},"Hopeful Aging",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":295,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":21,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":49},"100582380","pulsed-electromagnetic-field-treatment-with-dementia-patients-100582380","NCT06862557","Pulsed Electromagnetic Field Treatment With Dementia Patients","Effects of PEMF Treatment on Patients With Mild to Moderate Dementia in a Controlled Pilot Study","Inclusion Criteria:\n\n1\\. Age ≥ 50 years 2.2. Patients diagnosed with mild to moderate AD\u002FADRD including Alzheimer's disease, Lewy body dementia, and Vascular dementia - defined as a global CDR of 0.5 or 1 at baseline.\n\n3\\. At least an eighth grade of educational achievement 4. If female, post-menopausal. 5. MMSE score between 16 and 26 (inclusive) 6. Capable of providing consent or having a surrogate (e.g., spouse, family member) capable of providing consent if participant lacks consent capacity 7. Able and willing to comply with the protocol 8. If the participant is receiving a cholinesterase inhibitor and\u002For memantine, such medication has been prescribed for at least 3 months prior to screening and the dose is stable for at least 60 days prior to screening (that dose needs to be maintained throughout the period of this study) 10. Physical clearance for study participation as evaluated by the clinician\n\nExclusion Criteria:\n\n1. The patient lacks capacity to consent to study participation and no surrogate is available to provide consent\n2. The patient does not have a study partner who would be available for interview\n3. History of epileptic seizures or epilepsy\n4. Has Frontotemporal Dementia\n5. Currently taking medication that lowers the seizure threshold, excluding blood thinners\n6. Is currently taking anti-amyloid monoclonal antibodies (past treatment is allowed if termination of treatment occurred at least 3 months prior to the baseline visit).\n7. Presence of depression, bipolar disorder, a psychotic disorder, or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study\n8. Severe agitation that would interfere with study procedures\n9. Alcoholism or substance use disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation\n10. Major surgery (defined as any major abdominal, vascular or thoracic surgery requiring general anesthesia and resulting in a period of \\>1 week hospitalization) within 4 weeks\n11. Head anatomy that interferes with the fit of the treatment device\n12. Participation in another clinical trial within the previous 30 days\n13. Metal implants in the head, (i.e., cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants in mouth\n14. Criteria to exclude participants from the blood draw study:\n\nAny condition that may significantly increase risks associated with blood draws","50 Years","100 Years",{"count":298,"type":20},48,[23],"An open label pilot study in mild to moderate AD\u002FADRD patients to assess the effects of treatment with ECHS AD\u002FADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end point is the The Alzheimer's Disease Assessment Scale-Cognitive Subscale. Participants will be followed-up for 9 months post-treatment.",[302,303,31],"Alzheimer's Disease","Lewy Body Dementia",{"date":305,"type":41},"2025-05-18",{"date":307,"type":41},"2025-04-01",{"date":309,"type":20},"2026-09-30",{"name":311,"class":239},"Herrick Medical LLC",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":328,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":49},"100388301","enhancing-outcomes-in-cognitive-impairment-through-use-of-home-sleep-apnea-testing-100388301","NCT04335994","ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing","ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing: A Randomized Controlled Trial (ENCHANT Study)","ENCHANT","Inclusion Criteria:\n\n* Evidence of cognitive impairment by any one of: (i) Montreal Cognitive Assessment (MoCA) score of 13-28, or (ii) Mini Mental State Examination (MMSE) score of 18-30, or (iii) Toronto Cognitive Assessment (TorCA) score ≤281.\n* A diagnosis of: (i) Single-domain amnestic or multiple cognitive domain (with one feature being amnestic) Mild Cognitive Impairment due to Alzheimer's disease (AD); or (ii) Probable AD dementia; or (iii) Possible AD dementia due to limited concomitant cerebrovascular disease; or (iv) Probable Vascular dementia or Vascular Mild Cognitive Impairment, as per the 2011 American Heart Association Scientific Statement; or (v) Patients with a suspected neurodegenerative condition known to be associated with non-OSA sleep disorders (e.g. Parkinson's disease-related dementia and dementia with Lewy Bodies); and\u002For (vi) Mixed disease\n* Have the competency to provide informed consent, or the availability of a substitute decision maker\u002Fcaregiver who can provide consent (if needed).\n* The availability of a caregiver to assist in the completion of HSAT or iPSG, if needed.\n\nExclusion Criteria:\n\n* Prior diagnosis of OSA within the last 2 years\n* Patients already using CPAP or a dental appliance for previously diagnosed OSA.\n* A known contraindication for the use of the HSAT that will be used in this study: (a) Moderate to severe pulmonary disease or congestive heart failure that could compromise the validity of the HSAT results (in users of the ApneaLink); (b) Permanent pacemaker or history of sustained non-sinus cardiac arrhythmia (in users of the WatchPAT).\n* Any medical device that would interfere with the placement of the HSAT\n* Significant physical impairment or language barrier that would restrict the ability to use the HSAT or complete the study assessments.",{"count":321,"type":20},200,[23],"Obstructive sleep apnea (OSA), which causes abnormal pauses in breathing during sleep, is common in patients with vascular cognitive impairment (VCI) and Alzheimer's disease (AD), and exacerbates the cognitive deficits seen in these conditions. OSA is typically treated with continuous positive airway pressure (CPAP), which has been shown to improve cognition in VCI and slow cognitive decline in AD. Despite the need to identify OSA in patients with VCI\u002FAD, these patients often do not undergo testing for OSA. One major barrier is that in-laboratory polysomnography (iPSG), the current standard for diagnosing OSA, is inconvenient for patients with VCI\u002FAD who may be reliant on others for care or require familiar sleep environments. A convenient and cheaper alternative to iPSG is home sleep apnea testing (HSAT), which has been validated against iPSG to diagnose OSA and has proven feasible for use in VCI\u002FAD. Our primary objective is to determine whether the use of HSAT is superior to iPSG in terms of the proportion of patients who complete sleep testing by 6 months post-randomization. We will also investigate cost-effectiveness, patient satisfaction, proportion of patients treated with CPAP, changes in cognition, mood, sleep-related and functional outcomes between HSAT and iPSG at 6 months.",[325,28,31,64,326,193,327],"Obstructive Sleep Apnea","Parkinsons Disease With Dementia","Mixed Dementia",[325,329,330,331],"Cognitive Impairment","Home Sleep Apnea Test","Screening","2025-05-14",{"date":305,"type":41},{"date":335,"type":41},"2019-09-23",{"date":337,"type":20},"2027-06",{"name":339,"class":48},"Sunnybrook Health Sciences Centre",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":15,"sex":16,"minAge":100,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":354,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":49},"100522176","making-connections-thru-music-100522176","NCT06079216","Making Connections Thru Music","Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons With Dementia","MCTM","Inclusion Criteria:\n\n* Volunteers must be aged 55+ and speak\u002Fread conversational English.\n* Staff participants must be at least 18 years old, work within a residential care facility participating in the study, and speak and read English.\n\nExclusion Criteria:\n\n* Volunteers will be excluded if they are diagnosed with dementia based on self-report and\u002For if they score 23 or lower on theMini Mental State Exam (MMSE; Folstein et al., 1975). Such a score would be indicative of possible cognitive impairment.\n* Staff members will be excluded if they work third shift only. PWD Residents with dementia must be diagnosed with dementia (any type), score 10 or above on the MMSE, be aged 65+, and speak\u002Fread conversational English.\n* PWD will be excluded if they show signs of rapid physical or cognitive decline (based upon staff report or as evidenced by information gained during screening).","103 Years",{"count":350,"type":20},196,[23],"Healthcare systems around the world, including within the United States, have long-established shortages of trained caregivers. The American Health Care Association states that \"the health care system has experienced a shortage of trained caregivers for critical roles for some time.\" This scarcity directly impacts the 45,800 Long-Term Care (LTC) communities throughout the U.S.\n\nConcurrent with this staff shortage, more than half of LTC residents have some form of dementia. These two issues create a serious public health concern, since dementia is associated with a variety of behavioral expressions, such as aggression, anxiety, and agitation. Behavioral expressions of dementia can be successfully managed with the use of tailored, psychosocial interventions and communication support. Unfortunately, existing staff shortages make the facilitation of such interventions challenging.\n\nOne powerful and often-overlooked approach to ameliorating staffing shortages involves the utilization of retired volunteers to facilitate interventions for persons with dementia (PWD). Based on the nearly universal love of music and a promising pilot study, the product to be developed and tested in this STTR will build upon the combined prior work of the Principal Investigators. Making Connections Thru Music (MCTM), an urgently needed product, will enable retired volunteers to facilitate an evidence-based music and discussion intervention with PWD. MCTM aims to improve engagement, enhance quality of life, and reduce behavioral expressions in PWD. The intervention will consist of two main components: (1) a comprehensive online training course for volunteers, which will provide a general overview of dementia, demonstrate effective communication strategies to use with PWD, and instruct volunteers to effectively facilitate MCTM sessions, and (2) an app containing a structured MCTM intervention protocol and toolkit, which will be the means by which volunteers facilitate MCTM. MCTM will be marketed to LTC communities.",[26,28,31],"NOT_YET_RECRUITING","2025-01-15",{"date":357,"type":41},"2025-01-16",{"date":359,"type":20},"2025-07-01",{"date":361,"type":20},"2025-09-30",{"name":287,"class":239},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":371,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":49},"100512614","multidimensional-rehabilitation-programs-for-cognitive-impairment-in-comorbid-outpatients-a-randomized-controlled-trial-100512614","NCT05954741","Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial","Comparing the Effectiveness of Multidimensional Rehabilitation Programs for Cognitive Impairment in Comorbid Outpatients: a Randomized Controlled Trial","RCTCogRehab","Inclusion Criteria:\n\n* Age Between 65 and 80 years.\n* Neurocognitive Disorder due to vascular disease with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \\\u003C 12 months.\n* Neurocognitive Disorder due to multiple etiology with Clinical Dementia Rating Scale score between 0.5 and 1, symptoms onset \\\u003C 12 months.\n\nExclusion Criteria:\n\n* Other known neurological conditions involving cognitive functioning (e.g. Parkinson's disease, Multiple Sclerosis, head trauma, alcohol abuse).\n* Severe organic instability.\n* Neoplasia in progress.\n* Severe psychiatric condition.\n* Illiteracy.\n* Severe perception deficits.\n* Severe motor disability.\n* Specific intellectual deficit.\n* Participation in other forms of training or neurostimulation in the previous 6 months.\n* Pharmacological interventions of neurological pertinence in the month before the study.","80 Years",{"count":373,"type":20},75,[23],"Dementias secondary to cerebrovascular diseases are of significant epidemiological and clinical relevance. As a result, the management of individuals with comorbid dementia should involve early diagnosis, effective treatment, and patient-centered care planning, both in specialist and in non-specialist settings. It is well known that physical exercise can improve various aspects of health, including resistance, balance, strength, and cognitive functions such as attention and executive performance. However, the efficacy of cognitive rehabilitation is still not definitive and requires further clarification. Preliminary evidence suggests that a combination of cognitive and motor training along with novel technological approaches has the potential to maintain or improve compromised cognitive function more effectively compared to a single intervention. A multidomain intervention could enhance cognitive functioning in elderly individuals with multiple morbidities. In the present study, patients with early neurocognitive impairment based on a vascular disorder or due to multiple etiologies, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, will be screened in an outpatient multidisciplinary setting and subsequently undergo different models of rehabilitation training.\n\nPrimary aim of this study:\n\n\\- Assess the effectiveness of different rehabilitation protocols for improving cognitive functions in patients with comorbid cognitive impairment. Specifically, the investigators will test the effectiveness of three rehabilitation protocols (digital-based cognitive rehabilitation combined with motor rehabilitation, paper-based cognitive rehabilitation combined with motor rehabilitation, and motor rehabilitation alone) by means of a set of multidimensional outcome measures.\n\nSecondary aims:\n\n\\- evaluating the enhancement of cognitive performance using various cognitive questionnaires categorized by cognitive domains. Additionally, the investigators will examine multidimensional variables such as motor skills, mood and anxiety levels, quality of life, patient adherence to treatment, the role of communication in patient management, caregiver burden, and the usability of digital devices (when utilized).",[329,26,377,31,378],"Comorbidities and Coexisting Conditions","Dementia, Mixed",[26,380,381,382,383],"Comorbidity","Cognitive rehabilitation","Motor rehabilitation","Digital-based cognitive rehabilitation","2024-10-01",{"date":386,"type":41},"2024-10-03",{"date":388,"type":41},"2024-02-29",{"date":390,"type":20},"2026-01",{"name":392,"class":48},"Istituti Clinici Scientifici Maugeri SpA",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":15,"sex":16,"minAge":295,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":49},"100371332","longitudinal-cognitive-assessment-by-boca-100371332","NCT04114994","Longitudinal Cognitive Assessment by BoCA","BoCA","Inclusion Criteria:\n\nage 50 or older\n\nExclusion Criteria:\n\nyounger than 50 years",{"count":401,"type":20},10000,"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.",[28,64,31,30,29,404,405],"Multiple Sclerosis","TBI","2024-07-31",{"date":408,"type":41},"2024-08-01",{"date":410,"type":41},"2019-10-01",{"date":412,"type":20},"2029-10-01",{"name":414,"class":239},"Alzheimer's Light LLC"]